SEC Tracker
Get the app

INSMED INSM

INSMED appoints new directors

Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Paul Hudson and Utpal Koppikar appointed to Board effective Oct 19, 2026
  2. Hudson joins Compensation Committee, Koppikar joins Audit Committee
  3. Each receives $65,000 annual cash retainer and $585,000 RSU (shares paid out over time) grant
  4. No material interests or arrangements disclosed

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when INSMED files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biogen BIIB public float $18.4B, Jun 30, 2025
  2. Teva Pharmaceutical Industries TEVA public float $18.2B, Jun 30, 2025
  3. BeOne Medicines ONC public float $14.7B, Jun 30, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025